Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies

Financing led by Patient Square Capital with participation from leading life sciences investors to support  the further development of Kriya’s core technology platforms, advancement of its current programs and  continued expansion of its pipeline of gene therapies 

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., — July 14, 2021 — Kriya Therapeutics, Inc., a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy,  today announced the closing of a $100 Million Series B financing to support its mission of transforming  the design, development and manufacturing of gene therapies.  

The financing was led by Patient Square Capital, with participation from new investors Woodline  Partners LP, CAM Capital, Hongkou, Alumni Ventures and others. All existing institutional investors also  participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures,  Transhuman Capital, Narya Capital, Amplo and the Juvenile Diabetes Research Foundation T1D Fund.  Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand  its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and  oncology. 

“In recent years we have seen the promise of gene therapy become a reality for the treatment of a  number of devastating diseases. However, the field has been constrained by critical limitations in  manufacturing technology, vector design capabilities and cost,” said Shankar Ramaswamy, M.D., Co Founder and Chief Executive Officer of Kriya Therapeutics. “Kriya was formed with the mission of  revolutionizing how gene therapies are designed, developed and produced by fully integrating advanced  manufacturing technologies, computational tools, and development capabilities within a single  company. With the support of our new and existing investors, we believe that Kriya is well positioned to  deliver transformative improvements in cost, scale and efficiency that will help the gene therapy field  achieve its full potential across a range of therapeutic areas.” 

Concurrent with the financing, Jim Momtazee, Managing Partner of Patient Square Capital, will join  Kriya’s Board of Directors. Prior to Patient Square, Mr. Momtazee spent over 21 years at KKR, where he  helped establish the firm’s health care industry group in 2001 and subsequently was head of the  Americas Heath Care Investment Team for over 10 years. Mr. Momtazee has spent years on the board  of directors of Jazz Pharmaceuticals, HCA, PRA Health Sciences and BridgeBio Pharma, among other companies, and more recently joined the board of directors of Apollo Therapeutics. 

“We believe that gene therapy will have transformative impact on medicine over time, and companies  that are able to integrate platform capabilities delivering better treatments, lower cost and broader  applications of the technology are going to drive that innovation,” said Mr. Momtazee. “With that  vision, we are incredibly excited to partner with the management team at Kriya to bring multiple  important medicines to patients.”  

By combining advances in computer science and vector biology, Kriya is developing its SIRVE™ (System  for Intelligent Rational Vector Engineering) platform for de novo vector design, sequence modification  and data analysis. SIRVE is deployed to advance Kriya’s internally discovered gene therapy programs and  improve first-generation products, with a goal of reducing immunogenicity and improving expression 

and packaging efficiency. Kriya is also developing STRIPE™ (System to Realize Improved Production  Efficiency), a proprietary high-efficiency manufacturing platform integrating advances in cell line  technology and upstream and downstream process to achieve exponential reductions in production  costs at scale. STRIPE is being developed at Kriya’s 51,000 square foot manufacturing facility in Research  Triangle Park, North Carolina, and can support simultaneous manufacturing of multiple products from  early research through commercialization. The company’s full cGMP manufacturing infrastructure is expected to be online this year. 

About Patient Square Capital 

Patient Square Capital is a dedicated health care investment firm that partners with best-in-class  management teams whose products, services and technologies improve health. We utilize our deep  industry expertise, our broad network of relationships and a true partnership approach to make  investments in companies that will grow and thrive. We believe in the power these companies have to  improve patient lives, strengthen communities and create a healthier world. Patient Square is purpose built by a team of industry-leading executives, differentiated by the depth of our focus in health care,  the breadth of our health care investing experience, and the network we can activate to drive  differentiated outcomes. Most importantly, patients are squarely at the center of all that we do. For  more information, visit 

About Kriya Therapeutics 

Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and  therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed,  developed and manufactured – improving speed to market and delivering significant reductions in the  cost per dose. Kriya is built on two distinct technology platforms: its computationally enabled  proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency manufacturing  platform for scalable and low-cost production (STRIPE™). The company is advancing a deep and  diversified pipeline of innovative gene therapies spanning rare and prevalent diseases in multiple  therapeutic verticals, with current pipeline programs addressing metabolic, ophthalmic and oncologic  diseases. With locations in Silicon Valley, Calif., and Research Triangle Park, N.C., Kriya was founded by  pioneers in the biopharmaceutical industry and is backed by blue-chip life sciences and technology  investors. For more information, please visit and follow on LinkedIn. 


Media Contact:

Danielle Cantey 
Canale Communications 
[email protected] 
(619) 826-4657

Back To News